Preventive and Therapeutic Effect of Voglibose in Management of Diabetes Mellitus

Main Article Content

V.I. Pankiv

Abstract

The paper provided an overview of the effects of alpha-glucosidase inhibitors — one of the groups of oral hypoglycemic agents, which included in Standardized clinical protocol of primary and secondary health care in diabetes mellitus type 2. The main attention is paid to voglibose.

Article Details

How to Cite
Pankiv, V. “Preventive and Therapeutic Effect of Voglibose in Management of Diabetes Mellitus”. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine), no. 5.61, Sept. 2014, pp. 83-87, doi:10.22141/2224-0721.5.61.2014.76860.
Section
To practicing Endocrinologists

References

Abe M., Kikuchi F., Kaizu K. et al. Combination therapy of pioglitazone with voglibose improves glycemic control safely and rapidly in Japanese type 2-diabetic patients on hemodialysis // Clin. Nephrol. — 2007. — Vol. 68(5). — P. 287-294.

Geng D.F., Jin D.M., Wu W. et al. Effect of alpha-glucosidase inhibitors on the progression of carotid intima-media thickness: a meta-analysis of randomized controlled trials // Atherosclerosis. — 2011. — Vol. 218(1). — P. 214-219.

Kumar R.V., Sinha V.R. Newer insights into the drug delivery approaches of α-glucosidase inhibitors // Expert. Opin. Drug. Deliv. — 2012. — Vol. 9(4). — P. 403-416.

Saito N., Sakai H., Suzuki S. et al. Effect of an alpha-glucosidase inhibitor (voglibose), in combination with sulphonylureas, on glycaemic control in type 2 diabetes patients // J. Int. Med. Res. — 1998. — Vol. 26(5). — P. 219-232.

Santilli F., Formoso G., Sbraccia P. et al. Postprandial hyperglycemia is a determinant of platelet activation in early type 2 diabetes mellitus // J. Thromb. Haemost. — 2010. — Vol. 8(4). — P. 828-837.

Satoh N., Shimatsu A., Yamada K. et al. An alpha-glucosidase inhibitor, voglibose, reduces oxidative stress markers and soluble intercellular adhesion molecule 1 in obese type 2 diabetic patients // Metabolism. — 2006. — Vol. 55(6). — P. 786-793.

Takami K., Takeda N., Nakashima K. et al. Effects of dietary treatment alone or diet with voglibose or glyburide on abdominal adipose tissue and metabolic abnormalities in patients with newly diagnosed type 2 diabetes // Diabetes Care. — 2002. — Vol. 25(4). — P. 658-662.

Vannasaeng S., Ploybutr S., Nitiyanant W. et al. Effects of alpha-glucosidase inhibitor (acarbose) combined with sulfonylurea or sulfonylurea and metformin in treatment of non-insulin-dependent diabetes mellitus // J. Med. Assoc. Thai. — 1995. — Vol. 78(11). — P. 578-585.

Vichayanrat A., Ploybutr S., Tunlakit M. et al. Efficacy and safety of voglibose in comparison with acarbose in type 2 diabetic patients // Diabetes Res. Clin. Pract. — 2002. — Vol. 55(2). — P. 99-103.

Yamasaki Y., Katakami N., Hayaishi-Okano R. et al. Alpha-Glucosidase inhibitor reduces the progression of carotid intima-media thickness // Diabetes Res. Clin. Pract. — 2005. — Vol. 67(3). — P. 204-210.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 11 12 > >>